Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
Lung transplant recipients hospitalized with RSV face serious risks, with nearly 60% developing respiratory failure and over 17% needing mechanical ventilation. A new multicenter study found that older age and baseline oxygen use are key predictors of worse outcomes. Researchers say better prevention tools — like vaccines and monoclonal antibodies — are urgently needed for this vulnerable group.
Lung transplant recipients who contract RSV don't just get a bad cold — they face life-threatening complications. A retrospective study across seven international transplant centers found that among 155 hospitalized lung transplant patients with confirmed RSV, nearly 59% developed hypoxic respiratory failure and more than 17% required mechanical ventilation. The 90-day mortality rate was 7.7%, with most deaths occurring within three weeks of diagnosis.
The study identified clear risk factors: baseline oxygen use was linked to nearly fivefold higher odds of respiratory failure, lower respiratory tract symptoms nearly quadrupled the risk, and older age significantly raised the likelihood of needing mechanical ventilation. Secondary bacterial or fungal infections — including Pseudomonas aeruginosa and Staphylococcus aureus — occurred in one-third of patients, almost exclusively in those on ventilators.
By the Numbers:
Why it matters: Lung transplant recipients are among the most immunocompromised patients, and this study underscores how devastating RSV can be for them. The authors call for urgent research into prevention strategies — including RSV vaccines and monoclonal antibodies — tailored to this high-risk population.
